Key Challenges in CAR T-Cell Therapy Access in Community Oncology

This Viewpoint discusses the need to bring chimeric antigen receptor T-cell (CAR-T) therapy to community oncology, which will allow an uninterrupted continuum of care for patients.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2025-03-06
DOI
https://doi.org/10.1001/jamaoncol.2025.0042
Citations
2
Primary Topic
CAR-T cell therapy research
Type
article
Field-Weighted Citation Impact
2.09
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Key Challenges in CAR T-Cell Therapy Access in Community Oncology

Michael Byrne, Samyukta Mullangi, Aaron J. Lyss
2 citations
JAMA Oncology
CAR-T cell therapy research
2.09
article

Key Challenges in CAR T-Cell Therapy Access in Community Oncology

Michael Byrne, Samyukta Mullangi, Aaron J. Lyss
article en
2 citations

Abstract

This Viewpoint discusses the need to bring chimeric antigen receptor T-cell (CAR-T) therapy to community oncology, which will allow an uninterrupted continuum of care for patients.

JAMA OncologyVol. 11(5)
Tennessee Oncology (US)
Openalex Percentile: Top 14%
CAR-T cell therapy research
2.09
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Key Challenges in CAR T-Cell Therapy Access in Community Oncology — Michael Byrne, Samyukta Mullangi, et al. · JAMA Oncology (2025) | TGRS Research Map | TGRS